Reaktion #218731

ord-3b904661dd2c4aa69e8d5b38aafb0227

Reaktionsgleichung

CCCCCCCCCCCCCC(=O)O[C@@H]1[C@@H](C)[C@@]2(O)[C@@H](C=C(CO)C[C@]3(O)C(=O)C(C)=C[C@@H]23)[C@@H]2C(C)(C)[C@]12OC(C)=O.C[C@H](CCC(=O)O)C[C@H](C)C[C@H](C)C(=O)/C=C(\O)[C@H](C)C[C@H](C)C/C=C/[C@@H](C)[C@@H](O)[C@@H](C)[C@@H](O)C[C@@H]1CC[C@@](C)([C@H]2CC[C@@](C)([C@@H](C)O)O2)O1
PMA ionomycin
NC(=O)CC[C@H](N)C(=O)O
glutamine
CC1(C)S[C@@H]2[C@H](NC(=O)Cc3ccccc3)C(=O)N2[C@H]1C(=O)[O-].CN[C@@H]1[C@H](O[C@H]2[C@H](O[C@H]3[C@H](O)[C@@H](O)[C@H](NC(=N)N)[C@@H](O)[C@@H]3NC(=N)N)O[C@@H](C)[C@]2(O)C=O)O[C@@H](CO)[C@H](O)[C@H]1O.[K+]
penicillin streptomycin
C[C@H](CCC(=O)O)C[C@H](C)C[C@H](C)C(=O)/C=C(\O)[C@H](C)C[C@H](C)C/C=C/[C@@H](C)[C@@H](O)[C@@H](C)[C@@H](O)C[C@@H]1CC[C@@](C)([C@H]2CC[C@@](C)([C@@H](C)O)O2)O1
ionomycin

Lösungsmittel

Reaktionsbedingungen

Detaillierte Bedingungen
See reaction.notes.procedure_details.

Aufarbeitung

  1. 1
    SonstigeA 50-fold dilution of this was prepared in RPMI and serial dilutions
  2. 2
    Sonstigewere prepared from this solution
  3. 3
    workup.ADDITION10 μl of the 50-fold diluted stock, or dilutions of it, were added to the well
  4. 4
    Sonstigeto give
  5. 5
    Einengenconcentrations in the assay
  6. 6
    Sonstigeprepared from human peripheral blood from a single donor, in RPMI1640 medium
  7. 7
    EinengenPhorbol myristate acetate (PMA) (0.5 ng/ml final concentration) and ionomycin (500 ng/ml final
  8. 8
    Einengenconcentration)
  9. 9
    workup.ADDITIONwere added to these cells in supplemented RPMI1640 medium (as above) so that the final volume of the assay
  10. 10
    workup.ADDITION3H-Thymidine (0.5 μCi) was added for the final 6 hours of the incubation

Vorschrift

The assay for PMA/ionomycin-stimulated PBMC proliferation was performed in 96-well flat bottomed microtitre plates. Compounds were prepared as 10 mM stock solutions in dimethyl sulfoxide. A 50-fold dilution of this was prepared in RPMI and serial dilutions were prepared from this solution. 10 μl of the 50-fold diluted stock, or dilutions of it, were added to the well to give concentrations in the assay starting at 9.5 μM and going down. Into each well was placed 1×105 PBMC, prepared from human peripheral blood from a single donor, in RPMI1640 medium supplemented with 10% human serum, 2 mM glutamine and penicillin/streptomycin. Phorbol myristate acetate (PMA) (0.5 ng/ml final concentration) and ionomycin (500 ng/ml final concentration) were added to these cells in supplemented RPMI1640 medium (as above) so that the final volume of the assay was 0.2 ml. The cells were incubated at 37° C. in a humidified atmosphere at 5% carbon dioxide for 72 hours. 3H-Thymidine (0.5 μCi) was added for the final 6 hours of the incubation. The level of radioactivity incorporated by the cells was then determined and this is a measure of proliferation.

Quelle

DOI: 10.6084/m9.figshare.5104873.v1Patent: US07384950B2uspto-grants-2008_06